US 12,017,996 B2
Substituted quinolines and formulations thereof
Dawei Zhang, Thousand Oaks, CA (US)
Assigned to Jiangsu Medolution Ltd, Taizhou (CN)
Filed by JIANGSU MEDOLUTION LTD, Taizhou (CN)
Filed on May 10, 2022, as Appl. No. 17/740,364.
Claims priority of provisional application 63/186,755, filed on May 10, 2021.
Prior Publication US 2022/0371999 A1, Nov. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 215/54 (2006.01); C07D 401/04 (2006.01)
CPC C07D 215/54 (2013.01) [C07D 401/04 (2013.01)] 15 Claims
 
1. A pharmaceutical formulation comprising:
(i) about 20 mg of Compound A:

OG Complex Work Unit Chemistry
(ii) about 200 mg of mannitol;
(iii) about 10 mg of sodium starch glycolate;
(iv) about 1.1 mg of hydroxypropyl cellulose; and
(v) about 7 mg of glyceryl behenate.